DLP
BPMC

De Lisle Partners’s Blueprint Medicines BPMC Stock Holding History

De Lisle Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,000
Closed -$436K – 188
2024
Q4 		$436K Hold
5,000
– – 0.06% 175
2024
Q3 		$462K Hold
5,000
– – 0.07% 171
2024
Q2 		$539K Buy
+5,000
New +$500K 0.12% 151

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

De Lisle Partners's BPMC Position: Q1 2025 in Review

De Lisle Partners sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 5,000 shares — an estimated $436K sold.

De Lisle Partners first reported a position in BPMC in Q2 2024 and held it in 3 quarters. The position peaked at $539K in Q2 2024. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • De Lisle Partners reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
  • De Lisle Partners sold 5,000 Blueprint Medicines shares in Q1 2025, an estimated $436K.
  • De Lisle Partners first reported a position in Blueprint Medicines in Q2 2024 and held it in 3 quarters.
  • De Lisle Partners's Blueprint Medicines position peaked at $539K in Q2 2024.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on De Lisle Partners's 13F filing for Q1 2025, filed 8 May 2025.